Dr. Ann Beliën
Founder & Chief Executive Officer Rejuvenate Biomed
Dr. Ann Beliën is a biopharmaceutical leader with 22+ years of drug development expertise, from discovery to commercialization. As Founder and CEO of Rejuvenate Biomed, she has transformed the company from a startup into a clinical-stage biotech, securing international funding (Seed to Series B) and building a high-performing team. Her mission: developing mechanistic combination therapies to target age-related diseases and extend healthy longevity.
Previously, Dr. Beliën held key roles at Janssen Pharmaceuticals (Johnson & Johnson), including R&D Head of Strategy & External Innovation and board member of the Janssen Prevention Centre. She got her PhD at University of Zurich, and now she bridges deep research acumen with entrepreneurial vision. She specializes in due diligence, open innovation, and translational science, with a track record in both small and large molecules across multiple therapeutic areas. Dr. Beliën shares insights on Rejuvenate’s ambition to redefine healthy aging.
Seminars
- Integrating myostatin/activin inhibitors with GLP-1 agonists to preserve metabolic health and enhance long-term patient outcomes
- Leveraging biomarkers & phenotyping to guide patient stratification for combination therapies to identify responders to specific mechanisms
- Designing adaptive trials for multi targeted therapies to enable dosing optimisation and combination ratios for improved efficacy and tolerability
Join this session to explore how obesity trials and treatment paradigms must evolve with GLP-1 agonists as the new backbone therapy. Experts will debate optimal approaches for testing combinations and sequencing therapies, addressing critical questions about trial design, phenotypic targeting, and weight rebound mitigation.
- Determining patient-centric cardiometabolic endpoints to extend beyond weight loss while satisfying payer demands
- Combining dual GLP-1 and myostatin inhibitors to reduce muscle mass loss for greater metabolic health and explore composite endpoints that reflect real-world patient priorities to lower trial dropout rates
- Exploring sequential therapy protocols to reduce GI side effects for improved long-term adherence
- Reducing weight cycling by shifting focus from acute weight loss to sustained metabolic outcomes
- Reviewing the mechanistic rationale for multi-targeted therapies to achieve synergistic targeting of appetite suppression and muscle catabolism
- Comparing the analysis of body composition outcomes in recent trials to highlight trade-offs between fat loss efficacy, lean mass preservation, and tolerability
- Understanding the lessons from Phase 2 trials of multi-targeted obesity therapies to reveal practical challenges in dosing, patient adherence, and biomarker selection for body composition endpoints
